Literature DB >> 35433990

Using the apparent diffusion coefficient histogram analysis to predict response to neoadjuvant chemotherapy in patients with breast cancer: comparison among three region of interest selection methods.

Xiaochuan Geng1, Dandan Zhang1, Shiteng Suo1, Jie Chen1, Fang Cheng1, Kebei Zhang1, Qing Zhang1, Lan Li1, Yang Lu1, Jia Hua1, Zhiguo Zhuang1.   

Abstract

Background: The apparent diffusion coefficient (ADC) value using histogram analysis is helpful to predict responses to neoadjuvant chemotherapy (NAC) in breast cancer. However, the measurement method has not reached a consensus. This study was to assess the diagnostic performance of the ADC histogram analysis at predicting patient response prior to NAC in breast cancer patients using different region of interest (ROI) selection methods.
Methods: A total of 75 patients who underwent diffusion weighted imaging (DWI) prior to NAC were retrospectively enrolled from February 2017 to December 2019. Images were measured using small 2-dimensional (2D) ROI, large 2D ROI, and volume ROI methods. The measurement time and ROI size were recorded. Histopathologic responses were acquired using the Miller-Payne grading system after surgery. The inter- and intra-observer repeatability was analyzed and the ADC histogram values from the three ROI methods were compared. The efficacy of each method at predicting patient response prior to NAC was assessed using the area under the receiver operating characteristic curve (AUC) for the whole study population and subgroups according to molecular subtype.
Results: Among the 75 enrolled patients, 26 (34.67%) were responsive to NAC therapy. The ADC histogram values were significantly different among the three ROI methods (P≤0.038). Inter- and intra-observer repeatability of the large 2D ROI method and the volume ROI method was generally greater than that observed with the 2D ROI method. The 10% ADC value of the large 2D ROI method showed the greatest AUC (0.701) in the whole study population and in the luminal subgroup (AUC 0.804). The volume ROI method required significantly more time than the other two ROI methods (P<0.001). Conclusions: The small 2D ROI method is not appropriate for predicting response prior to NAC in breast cancer patients due to the poor repeatability. When choosing the ROI method and the histogram parameters for predicting response prior to NAC in breast cancer patients using ADC-derived histogram analysis, 10% of the large 2D ROI method is recommended, especially in luminal A subtype patients. 2022 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Breast neoplasms; diffusion magnetic resonance imaging; neoadjuvant therapy; observer variation

Year:  2022        PMID: 35433990      PMCID: PMC9011214          DOI: 10.21037/atm-22-1078

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Neoadjuvant chemotherapy (NAC) has been shown to increase the disease-free and overall survival rates in patients with operable breast cancer and represents an appropriate regimen for patients with locally advanced breast cancer (1,2). Predicting responsiveness to NAC may help to identify patients who will benefit from alternative therapeutic regimens. Imaging plays an important role in predicting response to NAC in breast cancer. The imaging method include ultrasound, mammography, Magnetic resonance imaging (MRI), integrated positron emission tomography (PET) with computed tomography (CT) (PET/CT) and PET/MRI, etc. The biomarkers for response prediction derived from imaging include tumor size (diameter, area, volume), apparent diffusion coefficient (ADC) value, signal enhancement ratio (SER), standard uptake value (SUV), etc. ADC aims at reflecting the biological properties of breast cancer trough parameters extracted from quantitative diffusion weighted imaging (DWI) that may change earlier before the morphological changes are detectable, during NAC. Although ADC value has been shown to be helpful in predicting a patient’s responses to NAC (3,4), there are some inconsistencies (5-11). These conflicting results might be partly attributed to the absence of a standardize measurement method applied to obtain ADC value. Moreover, the conventionally used average ADC value cannot fully reflect tumor heterogeneity, which may result from cancer nests, ductal components, intratumoral necrosis, or fibrosis (12). Recently, a histogram analysis method has been introduced to investigate tumor heterogeneity (13). The histogram method has been applied to predict the early response to NAC in patients with breast cancer and other types of malignancies (14-19). However, there is currently no consensus on the tumor region of interest (ROI) delineation method, some authors using volume ROIs method while others 2-dimensional (2D) ROIs (14,15,20,21). One study has applied histogram analysis to explore how ROIs can influence the measurement of the ADC value while predicting breast cancer response prior to NAC (22). Therefore, this current study investigated the repeatability of three ROI methods; assessed the influence of different ROI methods on ADC-derived histogram values; and compared the clinical feasibility of different ROI methods using ADC-derived histogram analysis in predicting a response in breast cancer patients prior to administration of NAC. We present the following article in accordance with the STARD reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-1078/rc).

Methods

Patients

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by institutional ethics board of Renji Hospital (No. KY2021-116-B). Informed consent was not required due to the retrospective nature of the study. A total of 106 patients, from Renji hospital clinical database between February 2017 and December 2019, were enrolled for this retrospective study. The inclusion criteria are displayed in . The inclusion criterials were applied: (I) Histologically confirmed breast cancer by core needle biopsy before NAC; (II) MRI prior to NAC; (III) NAC prior to surgery; (IV) surgery after NAC; (V) lesions measurable on ADC map. The following patients (n=31) were excluded: (I) 19 patients (61%) with poor image quality; (II) 6 patients (19%) with software unrecognizable; (III) 1 male patient (3%); and (IV) 5 patients (16%) with tumors containing large necrotic or cystic compartments. Finally, 75 female patients were recruited, with a mean age of 50 years (range, 26–73 years). The basic clinical characteristics of the patients are summarized in .
Figure 1

A flow chart of the study design depicting the number of patients. NAC, neoadjuvant chemotherapy; MRI, magnetic resonance imaging; ADC, apparent diffusion coefficient.

Table 1

Characteristics of the responders and non-responders before NAC

CharacteristicsResponders (n=26)Non-responders (n=49)P
Age (years), mean ± SD50±1250±110.965
Menstruation
   Y12280.364
   N1421
ER expression (%)18.35±32.1452.39±36.78<0.001*
PR expression (%)27.35±29.3036.98±32.190.208
HER2 expression
   Positive18210.030*
   Negative828
Luminal A
   Y5250.007*
   N2124
Luminal B
   Y14200.281
   N1229
Luminal type
   Y19450.029*
   N74
HER2 enriched
   Y410.027*
   N2248
Triple negative
   Y330.411
   N2346
TIC type
   I5130.580
   II1622
   III59
Enhanced pattern
   Mass22300.053
   Non-mass419
   D (cm), mean ± SD3.98±1.983.96±2.020.683
Size
   Small 2D ROI (cm2), median (IQR)0.15 (0.16)0.16 (0.22)0.684
   Large 2D ROI (cm2), median (IQR)5.58 (5.09)4.98 (6.63)0.832
   Volume ROI (cm3), median (IQR)12.39 (15.97)11.08 (16.61)0.920
Tumor type
   IC1118
   IDC1428
   ILC03
   Others10

*, indicates statistical significance (P<0.05). NAC, neoadjuvant chemotherapy; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TIC, time-intensity curve; D, maximum tumor diameter; 2D, 2-dimensional; ROI, region of interest; IQR, inter quartile range; IC, invasive carcinoma (which type of invasive carcinomas was not further classified); IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Y, yes; N, no.

A flow chart of the study design depicting the number of patients. NAC, neoadjuvant chemotherapy; MRI, magnetic resonance imaging; ADC, apparent diffusion coefficient. *, indicates statistical significance (P<0.05). NAC, neoadjuvant chemotherapy; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TIC, time-intensity curve; D, maximum tumor diameter; 2D, 2-dimensional; ROI, region of interest; IQR, inter quartile range; IC, invasive carcinoma (which type of invasive carcinomas was not further classified); IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Y, yes; N, no.

Histopathological analysis

Patients who responded to NAC therapy were defined by the absence of any identifiable invasive malignant cell or strictly ductal carcinoma in situ after surgery, according to the Miller-Payne grading system (23). The status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were assessed by immunohistochemistry. The ER and PR status were expressed as percentages (%). In classifying the HER2 gene expression, negative status was determined using scores of 0 and 1+, while positive status was determined by a score of 3+. When the score was 2+, fluorescent in situ hybridization (FISH) was performed to verify HER2 status (FISH+ positive). Breast cancer molecular subtypes were classified into three subtypes including luminal type, HER2-enriched, and triple negative, as described in previous studies (22,24-26). Luminal type was defined as tumor cells with nuclear ER and/or PR staining >10%. Luminal type breast cancers include two subtypes, luminal A and B. Luminal A was defined as ER and/or PR staining >10% and HER2 negative. Luminal B was defined as ER and/or PR staining >10% and HER2 positive. HER2-enriched was defined as ER and PR staining <10% with HER2 positive. Triple negative was defined as ER and PR staining <10%, and HER2 negative.

Magnetic resonance imaging (MRI)

All patients underwent MRI using a 3.0 T MR scanner (Philips Medical Systems, Achieva, Best, The Netherlands) in the prone position, using a four-channel breast array coil. All MR images were acquired using the following sequences: an axial DWI sequence, a fat-suppressed T2-weighted sagittal sequence, and an axial T1-weighted sequence. Finally, an axial dynamic contrast-enhanced MRI (DCE-MRI) was performed with three-dimensional (3D) T1-weighted fast spoiled gradient-echo sequences before and after injection of a contrast agent (0.1 mmol/kg body weight Gd-DPTA, Bayer Healthcare, Magnevist, Germany). For DWI, images were acquired with a single shot spin-echo-planar sequence, using the following parameters: repetition time/echo time (TR/TE), 2,681/82 ms; field of view, 230×240 mm; matrix, 224×224; slice thickness, 3 mm; 40 slices with 0 mm gap; number of excitation (NEX), 3; b-values, 0 and 800 sec/mm2.

Imaging analysis

Two breast radiologists (Xiaochuan Geng with 8 and Dandan Zhang with 2 years of experience in breast MRI) independently performed the ROI placements, which was repeated two months later. Both radiologists were blinded to the histological results and response to NAC. DWI image analysis was performed with MATLAB (MathWorks, version R2012b, Natick, Massachusetts, USA), and ADC maps were generated using a monoexponential model using the following formula: where S0 and Sb represent DWI signal intensity at b=0 and 800 s/mm2, respectively. Using lesion hyperintensity on high b-value DWI and DCE-MRI images as reference, ROIs were drawn manually on ADC maps using MATLAB. Necrosis, cystic, and hemorrhage sites were carefully avoided. Three ROI methods were applied (). The small 2D ROI method was delineated in the area where the lowest intensity inside the lesion was visualized. The large 2D ROI method covered a single slice showing the largest area of the whole lesion. The volume ROI method covered the whole lesion on all slices, that were then combined to form a 3D-ROI. The histogram of the ADC values was then calculated using the MATLAB software for every method. The parameters derived from the histogram analysis included the mean; standard deviation (SD); minimum; maximum; 10% and 25%, median, 75%, and 90% percentiles; skewness; and kurtosis. Finally, measurement time was computed using tic and toc functions on MATLAB. Skewness was used to measure the asymmetry, and kurtosis was used to measure the peakedness of the distribution (26). The ROI size, enhanced pattern, TIC type, were also recorded.
Figure 2

Images from a 49-year-old female patient with invasive ductal carcinoma confirmed by core needle biopsy in the left breast. (A) T1-weighted image. (B) Contrast-enhanced T1-weighted image. (C) DWI image with b=800 sec/mm2. (D) Small 2D ROI (arrow). (E) Large 2D ROI were delimited on the ADC map. (F) Three-dimensional rendering of the volume ROI covering the whole lesion. DWI, diffusion weighted imaging; 2D, 2-dimensional; ROI, region of interest; ADC, apparent diffusion coefficient.

Images from a 49-year-old female patient with invasive ductal carcinoma confirmed by core needle biopsy in the left breast. (A) T1-weighted image. (B) Contrast-enhanced T1-weighted image. (C) DWI image with b=800 sec/mm2. (D) Small 2D ROI (arrow). (E) Large 2D ROI were delimited on the ADC map. (F) Three-dimensional rendering of the volume ROI covering the whole lesion. DWI, diffusion weighted imaging; 2D, 2-dimensional; ROI, region of interest; ADC, apparent diffusion coefficient.

Statistical analysis

Continuous variables were expressed as mean ± SD or median [interquartile range (IQR)] according to the distribution. Categorical variables were presented as a count. The inter- and intra-observer repeatability for the 3 ROI methods were analyzed using interclass correlation coefficient (ICC; 0.00–0.20 represents poor correlation; 0.21–0.40 indicates fair correlation; 0.41–0.60 indicates moderate correlation; 0.61–0.80 represents good correlation; and 0.81–1.00 represents excellent correlation). The histogram ADC parameters (mean, standard deviation, minimum, maximum, median, 10%, 25%, 75%, 90% of ADC values) of the responders versus the non-responders were compared using unpaired Student’s t-tests for the 3 ROI methods. The differences in the histogram ADC parameters among the 3 ROI methods were compared using one-way analysis of variance (ANOVA). The measurement time was averaged and compared using paired-sample Student’s t-tests. Receiver operating characteristic (ROC) curves were constructed to assess the ability of the 3 ROI methods to differentiate responders from non-responders. According to arbitrary guidelines, the accuracy of prediction was defined as less accurate (AUC: 0.5–0.7), moderately accurate (AUC: 0.7–0.9), highly accurate (AUC: 0.9–1). Comparisons between ROC curves were performed with the method used by DeLong et al. (27). A P value less than 0.05 was considered statistically significant. Statistical analysis was performed using SPSS (IBM, version 21.0, Armonk, New York, USA), Medcalc (MedCalc Software Ltd., version 19.0.7, Ostend, Belgium) and EmpowerStats (2009 X&Y Solutions. Inc., IN, USA).

Results

Clinical characteristics

presents the clinical characteristics of the patients. Out of the 75 patients, 26 (35%) showed a histopathologically confirmed response. Based on the immunohistochemistry results, there were significant differences in the ER and HER2 status between responders and non-responders (P<0.001 and P=0.030, respectively; ). There were 5 (7%) HER2-enriched tumors, 6 (8%) triple negative tumors, and 64 (85%) luminal type breast cancers including 30 (40%) luminal A and 34 (45%) luminal B. A significant difference in the distribution of luminal type, luminal A, and HER2-enriched tumors was noted between responders and non-responders (P=0.029£, 0.007, and P=0.027, respectively). There was no significant difference in the size of the ROI.

Inter- and intra-observer repeatability analysis

Inter- and intra-observer repeatability of the large 2D ROI and volume ROI methods were generally higher than those of the small 2D ROI method. In the case of inter- and intra-observer repeatability associated with the large 2D ROI and volume ROI methods, intra-observer repeatability were generally higher than inter-observer repeatability, and some parameters (mean, 10%, 25%, median in large 2D ROI and mean, 10%, 25%, median, 75% in volume ROI) of the ICCs were excellent (0.820–0.934). The results are summarized in .
Table 2

Inter- and intra-observer repeatability for the three ROI methods

MetricsInter-observer ICCIntra-observer ICC
Small 2D ROI
   Mean0.6610.603
   SD0.0910.207
   Skewness0.1740.266
   Kurtosis0.2810.084
   Min0.6410.607
   10%0.6310.603
   25%0.6410.611
   Median0.6390.598
   75%0.5940.564
   90%0.5660.431
   Max0.5390.355
Large 2D ROI
   Mean0.8200.925
   SD0.4920.772
   Skewness0.4450.554
   Kurtosis0.2360.366
   Min0.4860.666
   10%0.8450.881
   25%0.860.912
   Median0.8210.934
   75%0.7660.921
   90%0.6850.88
   Max0.5190.788
Volume ROI
   Mean0.8460.906
   SD0.7650.793
   Skewness0.4410.662
   Kurtosis0.5450.761
   Min0.5980.505
   10%0.9240.875
   25%0.9100.913
   Median0.8320.905
   75%0.7870.883
   90%0.7640.867
   Max0.7530.744

All units of the parameters are ×10-3 mm2/s except for skewness and kurtosis. ROI, region of interest; ICC, intraclass correlation coefficient; 2D, 2-dimensional; SD, standard deviation; ROI, region of interest.

All units of the parameters are ×10-3 mm2/s except for skewness and kurtosis. ROI, region of interest; ICC, intraclass correlation coefficient; 2D, 2-dimensional; SD, standard deviation; ROI, region of interest.

A comparison of the ADC values among the three ROI methods

The ADC values of all patients were significantly different among the three ROI methods, with P<0.001 for all variables except for skewness (P=0.038) and the 10% percentile (P=0.006) (). The volume ROIs had the lowest minimum (0.17±0.17×10−3 mm2/s; P<0.001 compared with the minimum values of other ROI methods) and the largest maximum (2.33±0.55×10−3 mm2/s; P<0.001) ADC values.
Table 3

A comparison of ADC histogram values of the three ROI methods in all patients

MetricsSmall 2D ROILarge 2D ROIVolume ROIP
Mean0.82±0.251.09±0.241.10±0.22<0.001*
SD0.12±0.060.25±0.110.29±0.09<0.001*
Skewness0.25±0.680.23±0.550.45±0.500.038*
Kurtosis2.85±1.103.75±1.394.30±1.68<0.001*
Min0.62±0.270.41±0.330.17±0.17<0.001*
10%0.67±0.270.80±0.230.76±0.210.006*
25%0.73±0.260.93±0.230.91±0.21<0.001*
Median0.82±0.251.08±0.241.08±0.22<0.001*
75%0.89±0.251.24±0.261.27±0.25<0.001*
90%0.99±0.251.41±0.321.48±0.29<0.001*
Max1.07±0.291.90±0.602.33±0.55<0.001*

All units of the parameters are ×10−3 mm2/s except for skewness and kurtosis. *, indicates statistical significance (P<0.05). ADC, apparent diffusion coefficient; ROI, region of interest; 2D, 2-dimensional; SD, standard deviation.

All units of the parameters are ×10−3 mm2/s except for skewness and kurtosis. *, indicates statistical significance (P<0.05). ADC, apparent diffusion coefficient; ROI, region of interest; 2D, 2-dimensional; SD, standard deviation.

A comparison of the ADC values between responders and non-responders

Concerning the small 2D ROI method aspect, the mean, 10%, 25%, median, 75%, and 90% ADC values were all significantly higher in responders compared to non-responders (P≤0.049). In the large 2D ROI method, the minimum, 10%, 25%, and median ADC values were higher in responders compared to non-responders (P≤0.033). The same results were observed in the volume ROI minimum, 10%, 25%, and median ADC values (P≤0.041). Furthermore, the 10%, 25%, and median ADC values of the responders were significantly higher than those of non-responders in all 3 ROI methods ().
Table 4

A comparison of ADC histogram values between responders and non-responders

MetricsResponders (n=26)*Non-responders (n=49)*PSensitivity (%)Specificity (%)Cutoff value*AUC
Small 2D ROI
   Mean0.92±0.210.79±0.250.024#88.4640.820.7100.634
   SD0.12±0.060.12±0.060.82661.5448.980.1130.495
   Skewness0.22±0.620.27±0.710.75269.2344.900.1150.502
   Kurtosis2.96±0.872.80±1.190.56853.8567.352.8080.584
   Min0.72±0.240.59±0.270.06384.6234.690.5150.594
   10%0.77±0.230.64±0.280.044#84.6236.730.5620.594
   25%0.84±0.220.70±0.270.021#92.3136.730.5930.619
   Median0.92±0.210.78±0.250.020#88.4642.860.6980.644
   75%0.99±0.220.86±0.250.029#84.6242.860.7940.638
   90%1.08±0.230.96±0.260.049#50.0073.471.0480.643
   Max1.18±0.281.04±0.300.05688.4634.690.9110.624
Large 2D ROI
   Mean1.17±0.251.06±0.230.05469.2361.221.0670.647
   SD0.21±0.080.27±0.120.06284.6244.900.2550.619
   Skewness0.17±0.590.26±0.530.52188.4628.570.6210.558
   Kurtosis3.79±1.763.71±1.180.81026.9285.712.7190.517
   Min0.54±0.340.34±0.300.010#50.0079.590.6200.658
   10%0.90±0.230.74±0.220.004#80.7757.140.7500.701
   25%1.03±0.230.88±0.210.007#76.9255.100.8870.688
   Median1.17±0.251.04±0.220.033#57.6975.511.1280.645
   75%1.31±0.271.21±0.260.15369.2355.101.1960.616
   90%1.44±0.311.41±0.330.70480.7736.731.2480.548
   Max1.82±0.441.94±0.660.44073.0836.731.6140.470
Volume ROI
   Mean1.17±0.231.07±0.210.05780.7755.101.0330.648
   SD0.27±0.070.31±0.100.11346.1575.510.2470.577
   Skewness0.41±0.420.47±0.540.59642.3171.430.5770.486
   Kurtosis4.00±1.234.44±1.850.28846.1571.433.4450.562
   Min0.26±0.200.12±0.130.001#50.0087.760.2640.681
   10%0.85±0.210.72±0.210.008#84.6257.140.7120.686
   25%0.99±0.210.87±0.200.018#69.2365.310.9350.666
   Median1.16±0.231.05±0.210.041#76.9253.061.0230.650
   75%1.34±0.261.25±0.240.16157.6967.351.2790.620
   90%1.52±0.291.46±0.290.41669.2351.021.3960.586
   Max2.24±0.482.39±0.580.27776.9246.942.4490.580

ROC curves were generated for all ADC measurements for each ROI method. Sensitivity, specificity, and AUC were calculated under the optimal cut-off value listed for each item, which was determined according to the nearest point to the upper left corner of the ROC curve diagram. #, indicates statistical significance (P<0.05). *, all units of the parameters are ×10−3 mm2/s except for skewness and kurtosis. ADC, apparent diffusion coefficient; 2D, 2-dimensional; ROI, region of interest; SD, standard deviation; ROC, receiver operating characteristic; AUC, area under the curve.

ROC curves were generated for all ADC measurements for each ROI method. Sensitivity, specificity, and AUC were calculated under the optimal cut-off value listed for each item, which was determined according to the nearest point to the upper left corner of the ROC curve diagram. #, indicates statistical significance (P<0.05). *, all units of the parameters are ×10−3 mm2/s except for skewness and kurtosis. ADC, apparent diffusion coefficient; 2D, 2-dimensional; ROI, region of interest; SD, standard deviation; ROC, receiver operating characteristic; AUC, area under the curve. The ROC curves were generated to evaluate the diagnostic performances of the 3 ROI methods in predicting patient response (). All areas under the curve (AUCs) for the 3 ROI methods ranged from 0.470 (maximum of the large 2D ROIs) to 0.701 (10% of the large 2D ROIs) (). When a 10% ADC cutoff value of 0.75×10−3 mm2/s was used in the large 2D ROI method, the following diagnostic predictive values were acquired: sensitivity of 80.8%; specificity of 57.1%; positive predictive value (PPV) of 50.0%; negative predictive value (NPV) of 84.9%; and accuracy of 65.3%. The 10% area under the curve in large 2D ROIs was considered superior, however it was not significantly higher than 25% in the large 2D ROI method (AUC 0.688; P=0.589) and 10% in the volume ROI method (AUC 0.686; P=0.651).
Figure 3

ROC curves calculated from 3 ROI methods using ADC histogram analysis for discriminating between responders and non-responders prior to neoadjuvant chemotherapy. (A) Small 2D ROI method. (B) Large 2D ROI method. (C) Volume ROI method. ROC, receiver operating characteristic; 2D, 2-dimensional; ROI, region of interest; ADC, apparent diffusion coefficient.

ROC curves calculated from 3 ROI methods using ADC histogram analysis for discriminating between responders and non-responders prior to neoadjuvant chemotherapy. (A) Small 2D ROI method. (B) Large 2D ROI method. (C) Volume ROI method. ROC, receiver operating characteristic; 2D, 2-dimensional; ROI, region of interest; ADC, apparent diffusion coefficient.

A comparison of the histogram parameters between responders and non-responders according to molecular subtype

The histogram analysis results predicting response in different molecular subtype are displayed in and . Some histogram ADC values were significantly higher in responders with luminal A tumors using the 3 ROI methods, and responders with luminal type tumors using the large 2D and volume ROI methods, except for SD in the large 2D ROI method for luminal type patients. For luminal A breast cancer, the histogram parameters of the 3 ROI methods, with significant differences between responders and non-responders, had similar AUCs ranging from 0.744 to 0.804. In luminal A type, 10% of large 2D ROI method showed the highest AUCs (0.804), with the following diagnostic predictive values: sensitivity of 80.0%; specificity of 80.0%; PPV of 44.5%; NPV of 95.2%; cut-off value of 0.760×10−3 mm2/s; and accuracy of 80.0%. In luminal type, the SD of the large 2D ROI method had the highest AUC (0.689), with the following diagnostic predictive values: sensitivity of 89.5%; specificity of 46.7%; PPV of 41.5%; NPV of 91.3%; cut-off value of 0.255×10−3 mm2/s; and accuracy of 59.4%.
Table 5

A comparison of ADC histogram parameters between responders and non-responders according to molecular subtype

MetricsLuminal A (n=30)Luminal B (n=34)Luminal type (n=64)
Responders (n=5)*Non-responders (n=25)*PAUCResponders (n=14)*Non-responders (n=20)*PAUCResponders (n=19)*Non-responders (n=45)*PAUC
Small 2D ROI
   Mean0.93±0.300.70±0.240.0640.7360.88±0.240.85±0.230.7250.5070.89±0.250.77±0.240.0630.626
   SD0.16±0.100.12±0.070.3590.6320.10±0.050.12±0.050.4230.5930.12±0.070.12±0.060.8780.528
   Skewness0.13±0.460.16±0.550.9110.5280.28±0.720.47±0.850.5130.5540.24±0.660.30±0.710.7780.488
   Kurtosis2.52±0.722.35±0.770.6440.4163.23±0.953.35±1.510.7870.5323.04±0.942.80±1.250.4390.619
   Min0.65±0.340.50±0.290.3090.6400.69±0.270.65±0.240.6410.4860.68±0.280.57±0.270.1370.602
   10%0.72±0.320.54±0.290.2200.6640.75±0.260.71±0.230.6710.5180.74±0.270.61±0.270.0990.611
   25%0.83±0.330.60±0.270.1040.7200.80±0.260.77±0.230.6990.5290.81±0.270.67±0.270.0690.633
   Median0.92±0.320.70±0.240.0770.7120.87±0.240.83±0.230.5990.5390.89±0.250.76±0.240.0570.638
   75%1.02±0.310.78±0.230.0550.7280.93±0.240.91±0.240.8240.5230.95±0.250.84±0.240.0900.622
   90%1.14±0.310.87±0.230.028#0.8001.02±0.231.02±0.230.9520.4931.05±0.250.94±0.240.0790.627
   Max1.29±0.430.94±0.270.022#0.7601.10±0.271.12±0.280.8510.5251.15±0.311.02±0.290.1030.609
Large 2D ROI
   Mean1.14±0.290.99±0.230.2110.6841.12±0.261.14±0.210.8450.5041.13±0.261.05±0.230.2700.601
   SD0.18±0.050.29±0.150.1260.7760.21±0.090.25±0.080.2250.6520.2±0.080.27±0.120.035#0.689
   Skewness0.12±0.490.25±0.480.6130.5840.30±0.650.29±0.630.9520.4910.25±0.610.26±0.540.9480.488
   Kurtosis3.68±0.773.64±0.860.9210.5284.17±2.183.86±1.540.6270.5364.04±1.93.74±1.200.4440.528
   Min0.62±0.420.22±0.230.005#0.8000.50±0.340.45±0.330.7280.4550.53±0.360.33±0.300.022#0.677
   10%0.91±0.300.64±0.200.014#0.8040.87±0.230.85±0.210.7470.5410.88±0.240.73±0.230.019#0.682
   25%1.02±0.290.80±0.200.044#0.7440.99±0.230.97±0.200.8530.5250.99±0.240.87±0.220.0530.654
   Median1.14±0.300.97±0.230.1650.7041.11±0.251.13±0.210.8300.4911.12±0.261.04±0.230.2390.604
   75%1.25±0.301.15±0.280.4810.6481.26±0.281.29±0.230.6930.5271.25±0.281.21±0.260.5800.565
   90%1.35±0.291.36±0.370.9540.5121.39±0.341.47±0.270.4730.5611.38±0.321.41±0.330.7590.511
   Max1.71±0.292.00±0.850.4640.4361.82±0.511.92±0.390.5180.5861.79±0.461.96±0.680.3150.436
Volume ROI
   Mean1.13±0.221.03±0.210.3380.6361.13±0.251.12±0.190.8970.5431.13±0.241.07±0.210.3100.598
   SD0.28±0.070.32±0.130.5670.4720.26±0.080.30±0.060.1720.6210.27±0.080.31±0.100.1330.406
   Skewness0.40±0.370.40±0.340.9910.5080.45±0.480.55±0.720.6540.5340.44±0.450.47±0.540.8250.521
   Kurtosis3.94±1.214.22±1.470.6980.5604.18±1.384.92±2.360.3050.5894.12±1.314.53±1.920.4010.556
   Min0.29±0.210.08±0.07<0.001#0.7840.21±0.190.15±0.140.2660.5980.23±0.190.11±0.110.0030.671
   10%0.79±0.130.65±0.180.1180.7360.82±0.220.78±0.230.6460.5460.81±0.200.71±0.210.0840.642
   25%0.94±0.180.82±0.180.1720.6920.95±0.230.93±0.210.7270.5520.95±0.210.87±0.200.1370.623
   Median1.11±0.251.00±0.210.2980.6321.11±0.251.09±0.190.8250.5461.11±0.241.04±0.210.2510.598
   75%1.29±0.281.21±0.270.5560.6041.28±0.271.29±0.200.9610.5211.28±0.271.25±0.240.5730.561
   90%1.49±0.261.43±0.340.7310.5961.46±0.311.49±0.210.7330.5111.47±0.291.46±0.290.9040.537
   Max2.33±0.602.39±0.760.8630.5202.16±0.522.43±0.270.0600.6912.21±0.532.41±0.590.2030.605

#, indicates statistical significance (P<0.05); *, all units of the parameters are ×10−3 mm2/s except for skewness and kurtosis. ADC, apparent diffusion coefficient; 2D, 2-dimensional; ROI, region of interest; SD, standard deviation; AUC, area under the curve.

Figure 4

ROC curve to assess the differentiation between responders and non-responders prior to neoadjuvant chemotherapy in different subtypes. (A) 90%, max of small 2D ROI method, min, 10%, 25% of large 2D ROI method, min of volume ROI method in luminal A. (B) SD, min, 10% of large 2D ROI method, min of volume ROI method in luminal type. ROC, receiver operating characteristic; AUC, area under the curve; 2D, 2-dimensional; ROI, region of interest; SD, standard deviation.

#, indicates statistical significance (P<0.05); *, all units of the parameters are ×10−3 mm2/s except for skewness and kurtosis. ADC, apparent diffusion coefficient; 2D, 2-dimensional; ROI, region of interest; SD, standard deviation; AUC, area under the curve. ROC curve to assess the differentiation between responders and non-responders prior to neoadjuvant chemotherapy in different subtypes. (A) 90%, max of small 2D ROI method, min, 10%, 25% of large 2D ROI method, min of volume ROI method in luminal A. (B) SD, min, 10% of large 2D ROI method, min of volume ROI method in luminal type. ROC, receiver operating characteristic; AUC, area under the curve; 2D, 2-dimensional; ROI, region of interest; SD, standard deviation.

Measurement time

The average measurement time differed significantly among the 3 ROI methods (P<0.001) with the volume ROI method requiring significantly more time (80.36±42.95 s) than the small 2D ROI and the large 2D ROI methods (6.08±1.29 and 8.04±3.26 s, respectively; P<0.001).

Discussion

ADC histogram parameters may be useful in predicting the responsiveness of breast cancer patients to NAC prior to administration. This study compared the repeatability and diagnostic performance of different ROI placement methods, including the small 2D ROI, large 2D ROI, and volume ROI methods. The results demonstrated that the ADC histogram values varied with different ROI methods. The large 2D ROI and volume ROI methods had excellent intra- and inter-observer repeatability in some parameters. The performance of 10% in the large 2D ROI method was superior, even in luminal A subtype tumors. In addition, the volume ROI required an increased measurement time compared to the other two ROI methods. A number of reports have compared ROIs for breast cancer NAC response prediction (16,22,28). However, they failed to discuss the inter- and intra-observer repeatability and the volume ROI method was not included (16,22,28). In agreement with our findings, Newitt et al. reported good to excellent inter- and intra-observer repeatability for volume ADC, however, only mean values were reported (29). To the best of our knowledge, this current retrospective study is the first to examine the repeatability of three ROI methods in predicting response in breast cancer patients prior to NAC. The results demonstrated that the ICC of the median ADC value in intra-observer repeatability while using the large 2D ROI method was the highest, which was also higher than that reported in the study by Bickel et al. (highest ICC was obtained for the mean in the intra-observer using the large 2D ROI, 0.8848) (21). However, the large 2D ROI method in the latter study was different from the one presented in our study. Indeed, the authors delimited the whole lesion on one slice that had the lowest ADC values as assessed visually, which was more subjective than in our present study. Giannotti et al. confirmed that the ICCs in the intra-observer were higher than the inter-observer (30), and the ICCs using the large 2D ROI method were higher than those of the small 2D ROI method, in agreement with our results. However, Giannotti and colleagues did not mention the patient group pathology and only discussed the mean ADC value. For the small 2D ROI method, the ROI area could be very similar to the other regions of the lesion. It is difficult to reach a consensus for observers. Although having a statistical significance, the small 2D ROI method is not appropriate in predicting response, mainly due to its poor repeatability. Similarly, Arponen et al. reported that the ICCs of the large 2D ROI method (0.817 for intra-observer, 0.831 for inter-observer) were higher than those of the small 2D ROI method (0.707 for intra-observer, 0.589 for inter-observer) (31). In contrast, Nogueira and colleagues reported better inter-observer repeatability for the small 2D ROI method [ICC =0.98, confidence interval (CI): 0.986–0.997] (32). However, the latter investigation used fewer parameters than that used in the current study, such as the mean, median, minimum, maximum, and SD, and therefore, the heterogeneity of the breast cancer cannot be fully demonstrated. Significant differences in the histogram ADC values were detected among the 3 ROI methods. The volume ROIs were delineated slice by slice, while large 2D ROIs and small 2D ROIs contained only one slice. Indeed, the lowest and the highest cellular density may not occur in one slice. This explains why our volume ROI method had the lowest minimum and highest maximum ADC value. In conclusion, it is likely that ADC-derived histogram values can be influenced by the ROI method applied. ADC-derived histogram analysis might have the potential to predict patient response prior to NAC, especially in certain molecular subtypes of breast cancer. Most previous reports have suggested that the pretreatment ADC value cannot predict response to NAC in breast cancer patients (10,15,16,20,28,33,34). To our knowledge, only Kim et al., Cho et al., and Minarikova et al. have studied responses prior to administration of NAC using histogram analysis (14-16,20), and concluded that ADC values were not capable of predicting response. Our results are in contrast to the above mentioned studies. The disagreement may be related to the fact that we have included more histogram parameters than the previous studies (Kim et al.: mean, 25%, median, 75%, and skewness; Cho et al.: mean, SD, minimum, maximum, kurtosis, and skewness; and Minarikova et al.: mean, median, 15%, 25%, 75%, and 90%) (14-16,20). Our results, based on relatively lower parameters (10%, 25%, and median in both ROI methods), suggested that ADC-derived histogram values can discriminate responders from non-responders. The lower ADC parameters may represent the most malignant areas of breast cancer (26). Our outcomes showed that the largest AUC was acquired in 10% ADC value in the large 2D ROI, which was similar to Kim et al. (0.70 in 75% D) and higher than Minarikova et al. (0.673 in 25% ADC) (14,16). Moreover, the abovementioned authors did not include a further discussion on the influence of ROI methods. Our findings confirmed that, in the luminal A subtype, the diagnostic performance improved in the large 2D ROI and volume ROI methods. In breast cancers, different molecular subtypes have different prognosis and biological features, which are significantly relevant in clinical practice (35). Thus, it is important to choose an optimal ROI method for predicting NAC response depending on the different molecular subtypes in breast cancer. Bufi et al. reported an AUC of 0.787 in luminal type breast cancer, which is lower than that observed in our study (36). However, this latter investigation only used the large 2D ROI method and the mean for ADC values. Other authors have also failed to find any significance between responders and non-responders in luminal A or luminal type tumors (7,37). In these latter studies, only the 2D ROI method was used and only the mean for the ADC values was calculated. The AUC was the highest in the 10% of the large 2D ROI method in luminal A tumors, which was also the highest in the large 2D ROI method when molecular subtypes were not separated. Thus, our results showed that 10% in the large 2D ROI method is optimal for the luminal A subgroup, as well as for the whole study population, and the prediction performance was further improved in the luminal A subgroup. There were some limitations to this report. First, this was a retrospective study, which may have given rise to selection bias. And the study cohort was relatively small, thus the statistical power may be reduced. More detailed analysis according to subtypes such as HER2 enriched and triple negative could not be conducted. These initial results should be further confirmed with a larger sample size in the future. Second, the ROIs were measured manually rather than automatically. Third, ROIs were not compared during or after NAC, as some lesions had disappeared during or after NAC, and this may result in a substantial bias. However, this study is the first to focus on measurement methods in the prediction of NAC response in breast cancer patients using histogram analysis (14-16,20,38).

Conclusions

In conclusion, histogram ADC values can be influenced by the three ROI methods. The small 2D ROI method is not recommended in predicting response prior to NAC in breast cancer patients due to its poor repeatability. The predicting performance of ADC prior to NAC in breast cancer varies in different molecular subtype. When choosing the ROI method and histogram parameters in predicting response in breast cancer patients prior to NAC, 10% of the large 2D ROI method is recommended, in particular in luminal A subtype tumors. The article’s supplementary files as
  38 in total

1.  Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Raphael Richard; Isabelle Thomassin; Marion Chapellier; Aurélie Scemama; Patricia de Cremoux; Mariana Varna; Sylvie Giacchetti; Marc Espié; Eric de Kerviler; Cedric de Bazelaire
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

2.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

3.  Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer.

Authors:  Yunju Kim; Sung Hun Kim; Hye Won Lee; Byung Joo Song; Bong Joo Kang; Ahwon Lee; Yoonho Nam
Journal:  Magn Reson Imaging       Date:  2017-12-24       Impact factor: 2.546

4.  Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Sang Hee Park; Woo Kyung Moon; Nariya Cho; In Chan Song; Jung Min Chang; In-Ae Park; Wonshik Han; Dong-Young Noh
Journal:  Radiology       Date:  2010-10       Impact factor: 11.105

5.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

Review 6.  Current and future role of neoadjuvant therapy for breast cancer.

Authors:  Michael Untch; Gottfried E Konecny; Stefan Paepke; Gunter von Minckwitz
Journal:  Breast       Date:  2014-07-14       Impact factor: 4.380

7.  Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer.

Authors:  Hiroshi Fujimoto; Toshiki Kazama; Takeshi Nagashima; Masahiro Sakakibara; Tiberiu Hiroshi Suzuki; Yoshiyuki Okubo; Nobumitsu Shiina; Kaoru Fujisaki; Satoshi Ota; Masaru Miyazaki
Journal:  Breast Cancer       Date:  2013-02-12       Impact factor: 4.239

8.  Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.

Authors:  Foucauld Chamming's; Yoshiko Ueno; Romuald Ferré; Ellen Kao; Anne-Sophie Jannot; Jaron Chong; Atilla Omeroglu; Benoît Mesurolle; Caroline Reinhold; Benoit Gallix
Journal:  Radiology       Date:  2017-10-04       Impact factor: 11.105

9.  Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients.

Authors:  Gene Y Cho; Lucas Gennaro; Elizabeth J Sutton; Emily C Zabor; Zhigang Zhang; Dilip Giri; Linda Moy; Daniel K Sodickson; Elizabeth A Morris; Eric E Sigmund; Sunitha B Thakur
Journal:  Eur J Radiol Open       Date:  2017-08-18

10.  Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.

Authors:  Lenka Minarikova; Wolfgang Bogner; Katja Pinker; Ladislav Valkovič; Olgica Zaric; Zsuzsanna Bago-Horvath; Rupert Bartsch; Thomas H Helbich; Siegfried Trattnig; Stephan Gruber
Journal:  Eur Radiol       Date:  2016-09-20       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.